Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04572854 |
Recruitment Status :
Active, not recruiting
First Posted : October 1, 2020
Last Update Posted : March 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
C3G IC-MPGN Renal Transplant Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G) Dense Deposit Disease (DDD) Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN) Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulonephritis | Drug: Pegcetacoplan | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN |
Actual Study Start Date : | February 23, 2021 |
Actual Primary Completion Date : | February 27, 2023 |
Estimated Study Completion Date : | January 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Group 1
Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
|
Drug: Pegcetacoplan
Complement (C3) Inhibitor |
Group 2
No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
|
Drug: Pegcetacoplan
Complement (C3) Inhibitor |
- The primary efficacy endpoint is the proportion of subjects with reduction in C3c staining on renal biopsy after 12 weeks of treatment with pegcetacoplan. [ Time Frame: 12 weeks after randomization ]
- The proportion of subjects with reduction in C3c staining on renal biopsy [ Time Frame: 52 weeks after randomization ]
- The proportion of subjects with stabilization or improvement in estimated glomerular filtration rate (eGFR) [ Time Frame: 52 weeks after randomization ]
- The proportion of subjects with stabilization or improvement of serum creatinine concentration [ Time Frame: 52 weeks after randomization ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- At least 18 years of age at screening
- Must have clinical and pathologic evidence of recurrent C3G or IC-MPGN
- Stable (not improving) or worsening disease, in the opinion of the investigator, in the 2 months preceding the first dose of pegcetacoplan
- eGFR ≥15 mL/min/1.73 m2, calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation for adults
- No more than 50% glomerulosclerosis or interstitial fibrosis on the screening renal allograft biopsy
- Stable regimen for recurrent C3G/IC-MPGN for at least 4 weeks prior to the screening renal allograft biopsy and from the time of the screening renal allograft biopsy until randomization
- Have received required vaccinations against N. meningitidis, S. pneumoniae, and H. influenzae (type B) or agree to receive vaccinations, if applicable vaccination records are not available. Vaccination is mandatory unless documented evidence exists that subjects are non-responders to vaccination.
Exclusion Criteria:
- Absolute neutrophil count <1000 cells/mm3 during screening
- Previous treatment with pegcetacoplan
- Evidence of rejection on the screening renal allograft biopsy that requires treatment
- Diagnosis or history of HIV, hepatitis B, or hepatitis C infection or positive serology at screening indicative of infection with any of these viruses
- Weight more than 100 kg at screening
- Hypersensitivity to pegcetacoplan or any of the excipients
- History of meningococcal disease
- Malignancy, except for the following:
- Cured basal or squamous cell skin cancer
- Curatively treated in situ disease
- Malignancy free and off treatment for ≥5 years
- Significant renal disease in the renal allograft secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, rejection, or a medication) that would, in the opinion of the investigator, confound interpretation of the study results
- Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days or 5 half-lives from the last dose of the investigational agent (whichever is longer) prior to screening
- Known or suspected hereditary fructose intolerance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04572854
Responsible Party: | Apellis Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT04572854 |
Other Study ID Numbers: |
APL2-C3G-204 |
First Posted: | October 1, 2020 Key Record Dates |
Last Update Posted: | March 6, 2024 |
Last Verified: | March 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Glomerulonephritis Glomerulonephritis, Membranoproliferative Recurrence Disease Attributes Pathologic Processes Nephritis Kidney Diseases |
Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases Immune System Diseases |